Rhonda Patrick· PhD
And then you also have the clinical endpoints varying. So you have people looking at hospitalization. You'll have research groups looking at deaths. You'll have research groups looking at viral clearance time to a negative PCR. And in some cases, they're all being aggregated together, and it's like clinical benefit is the end point. And it's like, well, geez, these are vastly different clinical endpoints.